Old Web
English
Sign In
Acemap
>
Paper
>
PBI7 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
PBI7 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
2020
V. Ektare
R. Liu
Jennifer Stephens
A. Shelbaya
J. Yang
Keywords:
Biosimilar
budget impact
Bevacizumab
Medicine
Intensive care medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]